Transmission of antiretroviral-drug-resistant HIV-1 variants

被引:331
作者
Yerly, S
Kaiser, L
Race, E
Bru, JP
Clavel, F
Perrin, L [1 ]
机构
[1] Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp Geneva, Div Infect Dis, AIDS Unit, Geneva, Switzerland
[3] Hop Xavier Bichat, INSERM, Antiviral Res Lab, Paris, France
[4] Annecy Hosp Ctr, Div Infect Dis, Annecy, France
关键词
D O I
10.1016/S0140-6736(98)12262-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Resistance of HIV-1 to antiretroviral drugs is the main cause of antiretroviral-treatment failure. We assessed the transmission of drug-resistant variants among individuals with primary HIV-1 infection. Methods Population-based sequencing of the viral reverse transcriptase and protease genes derived from plasma viral RNA was done in 82 consecutive individuals with documented primary HIV-1 infection from January, 1996, to July, 1998. Phenotypic resistance to protease inhibitors was assessed by recombinant virus assay in individuals with two or more mutations associated with resistance to protease inhibitors. Findings Zidovudine-resistance mutations were detected in seven (9%) of 82 individuals. Mutations associated with resistance to other reverse-transcriptase inhibitors (RTls) were detected in two individuals. Primary-resistance mutations associated with protease inhibitors (V82A, L90M) were detected in three (4%) of 70 individuals; two of these had also RTI-resistance mutations. Decreased sensitivity to three or four protease inhibitors was seen in three individuals, one of whom was infected with HIV-1 variants that harboured 12 mutations associated with resistance to multiple RTI and protease inhibitors. Interpretation To introduce the best antiretroviral treatment, resistance testing should be done in recently HIV-1-infected individuals.
引用
收藏
页码:729 / 733
页数:5
相关论文
共 26 条
  • [11] Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
    Havlir, DV
    Marschner, IC
    Hirsch, MS
    Collier, AC
    Tebas, P
    Bassett, RL
    Ioannidis, JPA
    Holohan, MK
    Leavitt, R
    Boone, G
    Richman, DD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (18) : 1261 - 1268
  • [12] Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
    Hecht, FM
    Grant, RM
    Petropoulos, CJ
    Dillon, B
    Chesney, MA
    Tian, H
    Hellmann, NS
    Bandrapalli, NI
    Digilio, L
    Branson, B
    Kahn, JO
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (05) : 307 - 311
  • [13] Antiretroviral drug resistance testing in adults with HIV infection -: Implications for clinical management
    Hirsch, MS
    Conway, B
    D'Aquila, RT
    Johnson, VA
    Brun-Vézinet, F
    Clotet, B
    Demeter, LM
    Hammer, SM
    Jacobsen, DM
    Kuritzkes, DR
    Loveday, C
    Mellors, JW
    Vella, S
    Richman, DD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (24): : 1984 - 1991
  • [14] Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
    Imrie, A
    Beveridge, A
    Genn, W
    Vizzard, J
    Cooper, DA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (06) : 1502 - 1506
  • [15] Maintaining the integrity of human immunodeficiency virus sequence databases
    Learn, GH
    Korber, BTM
    Foley, B
    Hahn, BH
    Wolinsky, SM
    Mullins, JI
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (08) : 5720 - 5730
  • [16] SYMPTOMATIC PRIMARY INFECTION DUE TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 - REVIEW OF 31 CASES
    LOES, SKD
    DESAUSSURE, P
    SAURAT, JH
    STALDER, H
    HIRSCHEL, B
    PERRIN, LH
    [J]. CLINICAL INFECTIOUS DISEASES, 1993, 17 (01) : 59 - 65
  • [17] Impact of drug resistance mutations on virologic response to salvage therapy
    Lorenzi, P
    Opravil, M
    Hirschel, B
    Chave, JP
    Furrer, HJ
    Sax, H
    Perneger, TV
    Perrin, L
    Kaiser, L
    Yerly, S
    [J]. AIDS, 1999, 13 (02) : F17 - F21
  • [18] MAYERS DL, 1995, AIDS RES HUM RETROV, V11, pS162
  • [19] Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy:: Association with therapy failure
    Miller, V
    Phillips, A
    Rottmann, C
    Staszewski, S
    Pauwels, R
    Hertogs, K
    de Béthune, MP
    Kemp, SD
    Bloor, S
    Harrigan, PR
    Larder, BA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (06) : 1521 - 1532
  • [20] A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients - The INCAS trial
    Montaner, JSG
    Reiss, P
    Cooper, D
    Vella, S
    Harris, M
    Conway, B
    Wainberg, MA
    Smith, D
    Robinson, P
    Hall, D
    Myers, M
    Lange, JMA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (12): : 930 - 937